Financial Data and Key Metrics Changes - The company has a strong financial profile with significant cash flow and a growing balance sheet, indicating a robust near to medium-term outlook [5] Business Line Data and Key Metrics Changes - The company is focusing on the development of targeted therapies in the oncology and immunology sectors, particularly in myeloproliferative neoplasms (MPNs) and immune-mediated skin conditions [5][12] - The company plans to launch Jakafi XR in 2026, which is expected to preserve some revenue from Jakafi during the transition period [10][11] Market Data and Key Metrics Changes - The estimated market for essential thrombocythemia (ET) is approximately $5 billion, with a significant portion of that market being relevant for targeted therapies like 989 [21] - The total addressable market (TAM) for therapies targeting MPNs is projected to be around $7.5 billion, with potential penetration rates varying between 2% and 5.5% [45] Company Strategy and Development Direction - The company aims to establish a new standard of care for MPNs through the development of targeted therapies, with a focus on five different therapies currently under development [12][13] - The company is also exploring expansion opportunities in the immunology sector, particularly with Opsilura and Povo, which are expected to grow significantly in the coming years [52][54] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for product flow and the ability to build the company over the next decade, emphasizing the depth of scientific expertise within the organization [5][6] - The management team is optimistic about the upcoming data releases and the potential for pivotal trials in ET and myelofibrosis [16][20] Other Important Information - The company is actively engaging with regulatory bodies like the FDA to discuss pivotal trial designs and endpoints for their therapies [26][28] - The company has a backup plan for its 617F program, ensuring that it remains committed to addressing the needs of patients with MPNs [51] Q&A Session Summary Question: What is the opportunity in essential thrombocythemia (ET)? - Management highlighted that while ET is considered indolent, it is not benign, and there is a significant market opportunity for targeted therapies, particularly for high-risk patients [21][23] Question: What are the plans for pivotal trial design in ET? - The company is considering a straightforward design for pivotal trials in ET, focusing on complete hematologic response and potentially incorporating novel endpoints [25][26] Question: How does the company view the safety of combination therapies? - Management expressed confidence that the combination of their therapies with Jakafi would not present significant safety liabilities, based on preclinical data [42][43] Question: What is the growth potential for Opsilura and Povo? - The company anticipates double-digit growth for Opsilura and sees significant potential for Povo in the HS market, with plans for NDA submission in early 2026 [52][54] Question: What is the strategy for business development? - The company is focused on hematology, oncology, and immunology, with a clear strategy to build a portfolio rather than pursuing isolated assets [61][64]

Financial Data and Key Metrics Changes - The company has a strong financial profile in the near to medium term, with positive cash flow and a growing balance sheet [4] - The potential for meaningful product flow is highlighted, particularly in oncology and immunology markets [4] Business Line Data and Key Metrics Changes - The company is focusing on MPNs (myeloproliferative neoplasms) and has a pipeline that includes five different targeted therapies at various stages of development [11][12] - The launch of Jakafi XR is planned for 2026, which is expected to preserve some revenue from Jakafi during the transition period [9][10] Market Data and Key Metrics Changes - The ET (essential thrombocythemia) market is estimated to be around $5 billion, with a significant portion of that market being relevant for targeted therapies like 989 [19][20] - The total addressable market (TAM) for MPN therapies is projected to be approximately $7.5 billion, with the potential for significant penetration [42] Company Strategy and Development Direction - The company aims to create a new standard of care for MPNs, focusing on targeted therapies rather than traditional treatments [11] - There is a strategic emphasis on building a product line that can generate long-term durable revenue and earnings over the next decade [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to convert scientific advancements into business results, emphasizing the depth of scientific expertise within the organization [5] - The management team is optimistic about the potential for product flow and the company's positioning in structurally attractive markets [4] Other Important Information - The company is also focusing on its immunology franchise, with Opsilura and Povo showing strong growth potential [49][50] - Opsilura is expected to grow at a double-digit rate, with potential expansion opportunities in Europe and indications for moderate AD [50][62] Q&A Session Summary Question: What is the opportunity in the ET market? - Management highlighted that while ET is considered an indolent disease, it is not benign and can have serious consequences, indicating a significant market opportunity for targeted therapies [19][21] Question: How is the pivotal trial design for ET being approached? - The company plans to have a straightforward design for the pivotal trial, focusing on complete hematologic response and potentially incorporating novel endpoints [24][26] Question: What is the status of the 617F program? - The 617F program remains a priority, with ongoing data collection and a belief in its potential to benefit patients with the mutation [46][48] Question: How does the company view the competitive landscape in immunology? - The company acknowledges the competitive intensity in the HS market but believes in the unique benefits of Povo, particularly regarding pain relief and flare control [52][55] Question: What are the expectations for the oncology pipeline? - Management is excited about upcoming data presentations, particularly for the G12D program and TGF beta receptor two by PD-one bispecific, with a focus on demonstrating competitive profiles [71][73]

Group 1 - The Global Healthcare Conference features a special session with Incyte's new CEO, Bill Meury, marking his first appearance at an investor conference [1] - The conference also includes Incyte's President and Head of R&D, Pablo Cagnoni, highlighting the leadership presence at the event [2]

Summary of Incyte (INCY) 2025 Conference Call Company Overview - **Company**: Incyte Corporation (INCY) - **Date**: September 03, 2025 - **Focus**: Development of targeted therapies for hematology and immunology, particularly in myeloproliferative neoplasms (MPNs) and other conditions. Key Points Industry and Market Dynamics - The industry is facing a growth cliff that needs to be addressed for long-term sustainability [1] - Incyte is focused on building a product line that generates durable cash flows beyond just filling revenue gaps [2] Core Business and Product Pipeline - The core business includes products like Jakafi, Opzelura, Noctembo, and Monjuvi, with strong fundamentals expected to continue into Q3 and Q4 [2] - The late-stage pipeline includes povorcitinib, with an NDA submission planned for the first half of 2026 [3] - Incyte has a differentiated knowledge in MPNs, with five targeted therapies at various development stages [4] Financial Strategy and Resource Allocation - Incyte is reviewing its operating expenses and R&D spending, aiming for a balance between high-risk and sure-bet assets [13][11] - The company plans to maintain a disciplined approach to R&D, having terminated 15 programs in the past two years to focus on those that address medical needs and offer positive ROI [15][16] Product-Specific Insights - **Jakafi**: Expected to maintain $500 million to $750 million in revenue post-patent exclusivity, with a resubmission to the FDA planned for Jakafi XR [18] - **Opzelura**: Anticipated to grow at a 10% CAGR over the next five years, potentially doubling its revenue [21] - **Noctembo**: Projected sales between $300 million to $500 million, with ongoing studies to enhance its market position [24] Pipeline Developments - **INCB00989**: First targeted therapy for MPNs, showing promising results in normalizing platelets and reducing malignant clones [35][36] - **POVO**: The first oral therapy for hidradenitis suppurativa (HS) showing efficacy in pain reduction and inflammatory lesions, with a focus on its unique value proposition [52] Regulatory and Development Challenges - Incyte aims to engage with the FDA for a broader regulatory framework that reflects the unique mechanisms of their therapies [41][43] - The company is focused on integrating operationally seamless business development strategies, particularly in hematology and immunology [11][6] Future Outlook - Incyte is optimistic about its growth trajectory, with a focus on maintaining a robust pipeline and addressing evolving market needs [5][22] - The company is preparing for significant data releases in late 2026 and early 2027, which will further clarify its product positioning and market strategy [27][38] Additional Insights - The company emphasizes the importance of understanding the intrinsic value of business opportunities and maintaining a cautious yet aggressive approach to business development [11][7] - Incyte's leadership is committed to a disciplined R&D strategy, continuously evaluating programs against market needs and potential returns [16][12]

Core Insights - Allka Research has over two decades of experience in investment, focusing on uncovering undervalued assets in ETFs, commodities, technology, and pharmaceutical sectors [1] - The company emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [1] - Allka Research is committed to simplifying investment strategies, making them accessible to both seasoned and novice investors [1] - The mission of Allka Research includes sharing knowledge through Seeking Alpha, providing thought-provoking analyses and informed perspectives [1] - The goal is to demystify investing, inspire confidence, and foster a community of informed investors [1] Company Overview - Allka Research is recognized for its dedication to guiding individuals in finding lucrative investment opportunities [1] - The company thrives in a complex investment landscape by focusing on strategic insights and substantial returns [1] Investment Philosophy - The conservative approach of Allka Research sets it apart in the investment community [1] - The company aims to empower investors financially through education and accessible investment strategies [1] Community Engagement - Allka Research seeks to contribute to the Seeking Alpha community by sharing its wealth of knowledge [1] - The company aims to inspire confidence in readers, helping them navigate the financial markets intelligently [1]

Core Insights - Incyte (INCY) has shown strong performance, reaching a 52-week high of $87.24 on August 18, with a subsequent slight dip to $85.46, resulting in a 26.8% increase in stock price compared to the industry’s 6.3% gain [1][8]. Financial Performance - Jakafi sales increased by 15% to $1.5 billion in the first half of 2025, while Opzelura sales surged 37% year over year to $283 million during the same period [5][7][8]. - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen to $6.07 from $5.77 over the past 30 days, with the 2026 EPS estimate increasing by 36 cents to $7.49 [21]. Product Pipeline and Regulatory Updates - The FDA approved a cream formulation of ruxolitinib (Opzelura) for mild to moderate atopic dermatitis and non-segmental vitiligo, marking it as the first topical JAK inhibitor approved in the U.S. [6][8]. - Incyte's oncology portfolio has been bolstered by FDA approvals for Monjuvi and Zynyz, expanding treatment options for various cancers [9][12]. - The collaboration with Qiagen aims to develop a diagnostic panel for myeloproliferative neoplasms, enhancing Incyte's pipeline [13][14]. Competitive Landscape - Incyte's reliance on Jakafi for revenue growth is significant, as it accounts for over 70% of total revenues, and competition is increasing with new entrants like GSK's Ojjaara [15][16][23]. - The patent protection for Jakafi is expected to expire in the coming years, posing a potential risk to future revenue streams [17]. Management and Strategic Direction - Incyte has appointed Bill Meury as the new CEO, indicating a potential shift in strategic direction [23].

Core Viewpoint - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] Group 1: Market Performance - Since reaching a historical high on September 3, 2024, healthcare stocks have been in a "persistent downtrend," underperforming both in absolute terms and relative to the S&P 500 [1] - August is identified as a turning point for the sector, with healthcare stocks beginning to reverse their previous weak performance [1] Group 2: Economic Environment - The recovery is driven by a historically significant valuation gap and an economic backdrop characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors the healthcare sector [1] - The dual effect of valuation discount and improved sentiment provides strong justification for including healthcare stocks in investment portfolios under the current economic conditions [2] Group 3: Investment Recommendations - Evercore ISI highlights several healthcare stocks with attractive valuations and sentiment, including Cencora (COR.US), BioMarin Pharmaceutical (BMRN.US), Cigna (CI.US), Cardinal Health (CAH.US), Humana (HUM.US), Incyte (INCY.US), LabCorp (LH.US), Pfizer (PFE.US), Quest Diagnostics (DGX.US), Teleflex (TFX.US), Tenet Healthcare (THC.US), Universal Health Services (UHS.US), and Viatris (VTRS.US) [2]

Group 1 - The healthcare sector is showing initial signs of recovery after reaching a 30-year high in valuation discount relative to the S&P 500 index [1][2] - Healthcare stocks have been in a "persistent downtrend" since reaching historical highs on September 3, 2024, missing out on market rebounds [1] - The recovery is driven by a historical valuation gap and a macroeconomic environment characterized by GDP growth slowing to 1.5% or lower while inflation remains at 3% or higher, which historically favors healthcare sector performance [1] Group 2 - The current price-to-earnings ratio of the overall market is 25.5 times, while healthcare stocks still present attractive investment options [2] - The potential recovery of healthcare stocks is described as part of "the fastest bear market rebound in history," indicating a larger bull market may extend until 2026 [2] - Evercore ISI recommends healthcare stocks with both valuation and sentiment appeal, including Cencora, BioMarin Pharmaceutical, Cigna, Cardinal Health, Humana, Incyte, Labcorp, Pfizer, Quest Diagnostics, Teleflex, Tenet Healthcare, Universal Health Services, and Viatris [2]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum characteristics, with A being the highest score [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Style Score focuses on identifying undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future growth potential through earnings, sales, and cash flow analysis [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes to identify favorable investment opportunities [5] VGM Score - The VGM Score combines the three Style Scores to highlight stocks with the best value, growth, and momentum characteristics [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.75% since 1988 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down choices [8] Investment Strategy - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks, even with good Style Scores, may still face declining earnings forecasts, increasing the risk of price drops [10] Company Spotlight: Incyte Corporation - Incyte Corporation, based in Wilmington, DE, is a biopharmaceutical company focused on proprietary therapeutics [11] - Currently rated 3 (Hold) with a VGM Score of A and a Value Style Score of B, indicating attractive valuation metrics [12] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $5.77 per share for fiscal 2025 and an average earnings surprise of +4.2% [12]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12400 INCYTE CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction o ...